LONDON (AP) — AstraZeneca said Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease. The results are based on interim ...

AstraZeneca is the latest drugmaker to announce promising Phase 3 trial results from its COVID-19 vaccine candidate. On Monday, AstraZeneca said its two-shot vaccine candidate has been 90% effective ...

LONDON - AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the ...

CHICAGO, Dec 7 (Reuters) - A top U.S. scientist overseeing COVID-19 vaccine trials expects a large U.S. study to determine how effective AstraZeneca's experimental inoculation is, following perplexing ...

RIO DE JANEIRO (Reuters) - Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or ...

AstraZeneca says its U.S. trial showed its COVID vaccine is 79% effective in preventing symptomatic disease. Those trials involved more than 32,000 people. The shot is already approved in many ...

A single dose of the Oxford-AstraZeneca coronavirus vaccine is 76% effective for up to 90 days after vaccination, a new study out of the U.K. suggests. University of Oxford researchers published a ...

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% ...

SAN FRANCISCO -- Herculean efforts by scientists and physicians around the world have resulted more than 50 experimental COVID-19 vaccines currently in global clinical trials. The focus in the U.S.

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. LONDON (AP) — AstraZeneca said Monday that ...